New Trial Aims to Make Immunotherapy Work for the 95% of Rectal Cancer Patients It Can't Reach
· techtimes.com · popularity 20/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
BT-001, an armed oncolytic virus, enters Phase 1 clinical trial targeting pMMR rectal cancer — the 95% of patients who have no approved immunotherapy option.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 5.